Pacer Developed Markets International Cash Cows 100 ETF (BATS: ICOW)

Últimas noticias sobre Pacer Developed Markets International Cash Cows 100 ETF (BATS:ICOW)

Pacer Developed Markets International Cash Cows 100 ETF

Energy

Industrials

Basic Materials

Consumer Cyclical

Other

Communication Services

Consumer Defensive

Utilities

Healthcare

Technology

The fund will invest at least 80% of its total assets (exclusive of collateral held from securities lending) in the component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index uses an objective, rules-based methodology to provide exposure to large and mid-capitalization non-U.S. companies in developed markets with high free cash flow yields.

Kia Corp

Shell Plc

Deutsche Telekom Ag

Bp Plc ADR

Statoil Asa-Spon Adr

Eni Spa Adr

Canadian Nat Res

British American Tobacco Plc (ADR)

PCR ICOW UCITS ETF

News

Financing

Kite Realty Group Recasts $1.1B Unsecured Revolving Credit Facility And Amends $250M Term Loan Facility

LASE

Laser Photonics Corp Requests That Their Press Release Issued October 1, 2024 Titled "laser Photonics To Supply Cleantech Laser Cleaning Technology To Hemlock Semiconductor" Be Killed; The Release Was Issued In Error By Laser Photonics Corporation. A Replacement Release Will Not Be Issued.

AMERISAFE, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amsf#NASDAQ">AMSF</a>) is currently considered expensive on a relative basis, with the stock trading at a 22X forward 12-month price-to-earnings (P/E) ratio, which is at a premium compared with its five-year median of 20.21X and the Zacks&nbsp;Insurance - Accident and Health average of 13.36X. A premium valuation generally indicates that the market has strong confidence in the company&#39;s prospects. However, this necessitates scrutiny to determine if this higher price is warranted.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a5/80818.jpg?v=1155545738" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
In comparison, other insurers like&nbsp;Employers Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eig#NYSE">EIG</a>) and&nbsp;ProAssurance Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pra#NYSE">PRA</a>) are cheaper at 13.30X and 19.72X, respectively.
A brief analysis is needed to determine whether AMSF&#39;s premium valuation is justified based on its growth prospects and fundamentals.
Let&#39;s delve deeper.
Incorporated in 1985 and headquartered in DeRidder, LA, AMERISAFE currently has a market cap of $909.9 million. It is well positioned for growth, leveraging rising investment income and a robust balance sheet.
AMSF&#39;s extensive experience in hazardous industries and a high policy retention rate are major positives. Its cost-saving initiatives are expected to support its bottom line. Last year, it lowered loss and loss adjustment expenses by 2.7%.
The long time lag between receiving premiums and settling claims allows the company to invest funds for extended periods, compounding returns more effectively than insurers with quicker claim payouts, thereby boosting its investment income potential. Last year, it recorded a net investment income of $31.3 million, which advanced by 15.1%, resulting from increased fixed-income reinvestment rates. The first half of 2024 also witnessed higher reinvestment rates.
AMSF&#39;s solid balance sheet, with no debt and $884.2 million in investments and cash as of June 30, 2024, supports initiatives to boost shareholder value. The company raised its quarterly dividend by 8.8% in February 2024, continuing its steady dividend payments since 2013. In the second quarter, AMERISAFE repurchased $4.1 million worth of shares, with $6.3 million remaining in its buyback program as of June 30.
<h2>Should Investors Pay the Premium for AMSF?</h2>
The factors mentioned above have contributed to AMERISAFE&#39;s premium valuation, reflecting strong investor confidence in its future growth and profitability. As a result, investors are willing to pay a higher price for the stock, anticipating that it will outperform both its industry peers and the broader market in the coming months.
However, uncertainty surrounds the stock due to AMERISAFE&#39;s continuous decline in net premiums earned over the past five years. If this trend persists, it could potentially impede the company&#39;s ability to enhance its profits. The Zacks Consensus Estimate for 2024 earnings is pegged at $2.40 per share, indicating a 17.5% year-over-year decline. The same for 2025 signals a further 12.5% fall.
Also, AMERISAFE has faced a downward trend in free cash flow from 2018 to 2022, indicating potential operational challenges. While it saw a 12.2% increase in 2023, the sustainability of this growth is uncertain. In the trailing 12 months, free cash flow dropped sharply by 56.7%, raising concerns about the company&#39;s long-term financial health.
Despite these headwinds, the company&#39;s overall outlook remains positive. Leading brokers have raised AMSF&#39;s short-term price target by 12.47% from its recent closing price of $47.72, with the highest target set at $65, representing a potential upside of 36.21%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/06/80819.jpg?v=1182891382" style="border-style:solid; border-width:1px; height:315px; width:600px" />
Image Source: Zacks Investment Research
Existing investors should hold onto AMERISAFE stock to capitalize on its upward price movement. However, new investors might want to wait for a better entry point. Currently, the stock has a Zacks Rank #3 (Hold) and appears overvalued, suggesting that it may not be the ideal time to buy. Waiting for a more attractive valuation could present a better opportunity to invest.
<a href="https://www.zacks.com/stock/news/2347764/is-amerisafe-stock-a-pricey-pick-or-a-hidden-gem-for-your-portfolio?cid=CS-BENZ-FT-analyst_blog|rank_focused-2347764">To read this article on Zacks.com click here.</a>

Earnings

Dividends

Price Target

Buybacks

Small Cap

Markets

Analyst Ratings

Trading Ideas

Insurance

AMSF

Is AMERISAFE Stock a Pricey Pick or a Hidden Gem for Your Portfolio?

In the current session, the stock is trading at $161.40, after a 0.09% spike. Over the past month, Booz Allen Hamilton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) stock increased by 6.29%, and in the past year, by 27.44%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1728418508_0.png" alt="Past Year Chart" />

<h3>How Does Booz Allen Hamilton P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Booz Allen Hamilton has a lower P/E than the aggregate P/E of 46.25 of the Professional Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1728418508_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Booz Allen Hamilton

VXRT

Vaxart Provided Notice To Sales Agents To Terminate Sales Agreement, Effective Oct 18; Will Not Incur Any Termination Penalties As Result Of Termination

Getting income from stock investments is why many invest in certain companies. It can provide a stable cash stream while offering the benefit of potential appreciation in stock price. However, companies must balance how much they pay their shareholders through dividends and how much they retain to reinvest back in their business.
If a company has valuable projects to pursue but lacks cash, its high dividends could hurt shareholders in the long run. One way to measure a company&#39;s ability to reinvest is to look at the dividend payout ratio (DPR). This ratio shows the percentage of the company&#39;s earnings it pays out as dividends.
If the dividend payout ratio is too high, the company might not have the cash it needs to invest in potentially high-return projects in the future. This could include making large capital expenditures (CAPEX) or strategically acquiring another firm.
The inability to do this could negatively affect the stock price over time or prevent it from rising as much as it otherwise could. Below, I&#39;ll review three U.S. stocks with dividend yields over 5% and dividend payout ratios that allow for solid reinvestment back into their business. For this analysis, I&#39;ll use these companies&#39; next twelve-month (NTM) dividend yield, which is an average of analyst projections for the company&#39;s dividend yield.
<h2>Ford Motor: Lots of Dividend Income and Lots Left Over</h2>
First up is Ford Motor (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/f#NYSE">F</a>). Ford&#39;s NTM dividend yield of 5.6% is relatively high, and its dividend payout ratio over the last twelve months is low. It sits at just 13.8%, meaning that the company is retaining over 86% of its earnings to reinvest back into the firm. Based on the company&#39;s net income over the last twelve months, it has been over $3.3 billion, and the company has to put it toward different uses.
This gives Ford the flexibility to invest in projects, initiate a share buyback program, or increase dividends. This is crucial, as the automotive industry is capital-intensive, requiring significant investments in plants, property, and equipment to stay competitive. With the global shift toward electric vehicles, maintaining financial flexibility will help Ford remain nimble, allowing the company to adapt to market changes and meet evolving customer preferences. This ability to invest strategically is key to Ford&#39;s long-term success in the rapidly changing automotive landscape.
<h2>AT&amp;T: 5% Dividend While Investing Big in Fiber Optics</h2>
AT&amp;T (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>) is a telecom company that provides big-time income to its shareholders while not overextending its commitments. Its 5.1% NTM dividend yield offers a solid base of return. Its dividend payout ratio is 64%. It&#39;s a bit higher than I would like to see, but it&#39;s below 75%, where concerns about sustainability may arise. Again, its industry is key to why the company must retain earnings to compete effectively. AT&amp;T is investing heavily in fiber optics to connect more homes and businesses to the Internet.
Building fiber optic networks requires digging trenches on land or underwater or building above-ground cable systems. These cables physically connect buildings to centralized data centers, allowing for faster internet speeds. Thus, these investments require significant CAPEX from AT&amp;T. The company is doing just that, having spent $17.4 billion in CAPEX over the last twelve months. Fiber optics investments are vital to the firm&#39;s strategic plan to compete with large telecom firms.
<h2>Ares Capital&#39;s Dividend Strategy Balances Payouts and Growth Potential</h2>
Last on the list is Ares Capital (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arcc#NASDAQ">ARCC</a>). Ares is a business development company (BDC). BDCs invest in private companies using both debt and equity. Because of this, investing in Ares is an indirect way to gain some exposure to private debt and private equity, making Ares an interesting stock. On top of this, Ares also provides its shareholders a massive dividend yield.
Analysts project the number to sit at just under 9.3% over the next twelve months. In addition, its dividend payout ratio is 63%. Again, maybe a bit on the high side, but Ares is not in an industry that requires much in the way of capital expenditures.
However, retaining more of its net income does allow the company more &quot;dry powder&quot; to invest with. This means that if it sees an opportunity that could bring in particularly high returns but requires a large upfront investment, it could be more capable of executing the deal.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/maximize-your-returns-3-dividend-stocks-with-yields-over-5/">Maximize Your Returns: 3 Dividend Stocks With Yields Over 5%</a>&quot; first appeared on MarketBeat.

Large Cap

Offerings

ARCC

Maximize Your Returns: 3 Dividend Stocks With Yields Over 5%

DA Davidson analyst Peter Heckmann maintains Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) with a Buy and maintains $136 price target.

EEFT

DA Davidson Maintains Buy on Euronet Worldwide, Maintains $136 Price Target

DA Davidson analyst Brent Thielman maintains Apogee Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) with a Neutral and raises the price target from $65 to $75.

APOG

DA Davidson Maintains Neutral on Apogee Enterprises, Raises Price Target to $75

WIIM

CRDL

Cardiol Therapeutics shares are trading lower after the company announced a preliminary prospectus for a proposed public offering of common stock, size or amount not disclosed.

The new platform fundamentally changes how the company builds products and will provide expanded commerce capabilities like Pre-Auth and Bar Tabs to sellers of all sizes across verticals in the U.S.

Square Reports General Availability Of New Orders Platform

Management

SANA

Sana Biotechnology Announces Susan Wyrick Appointed Interim CFO Of Co

Crocs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crox#NASDAQ">CROX</a>) stock seems in a good spot since the past year, with shares rising more than 60%, comfortably outperforming the broader Consumer Discretionary sector&#39;s return of 18.5% and the Zacks Textile - Apparel industry&#39;s growth of 4.8% in the same period. CROX&#39;s shares have also surpassed the S&amp;P 500 index&#39;s appreciation of 34.3% in a year.
Currently priced at $136.54, CROX stock is trading at 17.4% to its 52-week high of $165.32, reached on June 20, 2024. However, it is trading at an 84.5% premium to its 52-week low mark.
<h2>CROX&#39;s Strategies Aid the Rally</h2>
The company has been gaining from solid consumer demand across its Crocs and HEYDUDE brands, backed by effective pricing actions. Strength in clogs, sandals and personalization is acting as a tailwind. CROX has built various successful franchises, focused on expanding new usage occasions to boost new and repeat purchases. The sandal category further strengthened as consumers gave positive feedback to its innovation.
Management continues to view personalization as a mega consumer trend, with the opportunity of expanding the Jibbitz penetration in 2024 via higher penetration within digital and wholesale channels, continuous product freshness innovation and advancement in market capabilities. The company has been evolving its partnership model to boost engagement and consumer love.
<h2>CROX&#39;s Price Performance</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c6/80801.jpg?v=1226149498" />
Image Source: Zacks Investment Research
Crocs aims at solidifying the business in North America and developing Wendy and Wally as iconic franchises. The company brought new HEYDUDE partnerships to the market, which include Corona, a four-piece collection with the iconic beverage band, featuring Wally, Wendy and Hudson Styles. Its Lee partnership, Denim and Dudes, highlighted the first HEYDUDE collaboration with international reach.
Crocs is on track with its long-term strategy and key initiatives to deliver sustainable growth. Its growth strategy is focused on three key initiatives. The first key initiative is igniting icons to enhance brand awareness and relevance. The second is investing strategically in Tier 1 markets to drive market share gains via talent, marketing, digital and retail. The third initiative is diversifying the product range to attract new consumers.
<h2>Earnings Estimate Revisions Favor Crocs</h2>
The aforesaid catalysts have prompted analysts to remain optimistic about CROX. The Zacks Consensus Estimate for 2024 and 2025 earnings has been northbound. In the past 30 days, the consensus estimate for earnings per share has been revised 0.3% to $12.88 for 2024 and 0.2% to $14.00 for 2025.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c6/80815.jpg?v=687041234" />
Image Source: Zacks Investment Research
<h2>Unlocking CROX Stock&#39;s Valuation</h2>
Crocs stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, CROX&nbsp; is currently trading at 9.91 on a forward 12-month basis, lower than 12.68 of the industry. Also, the stock is trading lower than the S&amp;P 500 index&#39;s 21.69.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c6/80814.jpg?v=1442318185" />
Image Source: Zacks Investment Research
<h2>Final Words on CROX</h2>
CROX stock is performing well on the bourses given its solid strategic efforts including strength in its brands. Solid upward revisions in earnings estimates and attractive valuation for the stock seem encouraging as well.
To wrap up, Crocs seems to be an attractive investment bet given all the aforementioned positives. The company currently sports a Zacks Rank #1 (Strong Buy).
<h2>Other Solid Picks</h2>
We have highlighted three other top-ranked stocks, namely, G-III Apparel Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/giii#NASDAQ">GIII</a>), Royal Caribbean (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcl#NYSE">RCL</a>) and lululemon athletica (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>).
G-III Apparel is a manufacturer, designer and distributor of apparel and accessories under licensed brands, owned brands and private label brands. It sports a Zacks Rank of 1 at present.
GIII Apparel has a trailing four-quarter earnings surprise of 118.2%, on average. The Zacks Consensus Estimate for GIII Apparel&#39;s current financial-year sales indicates growth of 3.3% from the year-ago figure.
Royal Caribbean carries a Zacks Rank #2 (Buy) at present. RCL has a trailing four-quarter earnings surprise of 18.5%, on average.
The Zacks Consensus Estimate for RCL&#39;s 2024 sales and EPS indicates an increase of 18.2% and 70.9%, respectively, from the year-ago levels.
lululemon athletica is a yoga-inspired athletic apparel company. LULU carries a Zacks Rank of 2 at present.
The Zacks Consensus Estimate for lululemon athletica&#39;s current financial-year sales and EPS indicates growth of 9.2% and 9.8%, respectively, from the year-ago corresponding figures. LULU has a trailing four-quarter earnings surprise of 7.9%, on average.
<a href="https://www.zacks.com/stock/news/2347760/crocs-gains-on-brand-strength-other-efforts-apt-to-stay-invested?cid=CS-BENZ-FT-analyst_blog|rank_focused-2347760">To read this article on Zacks.com click here.</a>

Mid Cap

CROX

GIII

LULU

Crocs Gains on Brand Strength & Other Efforts: Apt to Stay Invested?

Shipping in pre-production quantities, Scorpio Smart Fabric Switches deliver maximum system utilization and uptime for scale-out PCIe 6 connectivity and scale-up GPU clustering in AI servers
Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>), a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced a new portfolio of fabric switches, including the industry's first PCIe&#xAE; 6 switch, built from the ground up for demanding AI workloads in accelerated computing platforms deployed at cloud-scale. The Scorpio Smart Fabric Switch portfolio is optimized for AI dataflows to deliver maximum predictable performance per watt, high reliability, easy cloud-scale deployment, reduced time-to-market, and lower total cost of ownership.

ALAB

Astera Labs Introduces New Portfolio Of Fabric Switches Purpose-Built For AI Infrastructure At Cloud-Scale

DA Davidson analyst Michael Baker maintains Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) with a Buy and maintains $24 price target.

DA Davidson Maintains Buy on Superior Gr of Cos, Maintains $24 Price Target

ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2024</td>
<td>2023</td>
<td colspan="2">$ Increase</td>
<td colspan="1">% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended September 30,</td>
<td>$6.0 million</td>
<td>$5.4 million</td>
<td colspan="2">$615,000</td>
<td>11%</td>
</tr>
<tr>
<td>During the Nine-Month Periods Ended September 30,</td>
<td>$18.7 million</td>
<td>$12.4 million</td>
<td colspan="2">$6.4 million</td>
<td>51%</td>
</tr>
<tr>
<td>During the Twelve-Month Periods Ended September 30,</td>
<td>$23.8 million</td>
<td>$16.3 million</td>
<td colspan="2">$7.6 million</td>
<td>46%</td>
</tr>
</tbody>
</table>
</figure>
 During the three-, nine- and twelve-month periods ended September 30, 2024, annualized production output was approximately 73%, 81% and 77%, respectively, of the Company's estimated full capacity of approximately $30 million per year.
As of September 30, 2024, the backlog of orders aggregated approximately $7.3 million. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of the first quarter calving season.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.

Guidance

ICCC

ImmuCell Announces Preliminary Q3 Revenue Of $6M Up From $5.4M YoY

Saratoga Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) reported quarterly earnings of $1.33 per share which beat the analyst consensus estimate of $0.94 by 41.49 percent. The company reported quarterly sales of $43.003 million which beat the analyst consensus estimate of $37.124 million by 15.84 percent. This is a 21.09 percent increase over sales of $35.514 million the same period last year.

Earnings Beats

Saratoga Investment Q2 2025 Adj. EPS $1.33 Beats $0.94 Estimate, Sales $43.003M Beat $37.124M Estimate

MYGN

Myriad Genetics Reveals Series Of Ongoing Research Collaborations To Study Use Of Molecular Residual Disease Testing In Breast Cancer Using Precise MRD Test

—Data Presented at the CHEST 2024 Annual Meeting—
BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4272617-1&amp;h=1623866854&amp;u=https%3A%2F%2Finvestor.insmed.com%2Fevents%3Fitem%3D127&amp;a=HERE">HERE</a>. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed's respiratory portfolio.

Biotech

General

INSM

Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting

Delek Logistics Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKL#NYSE">DKL</a>) ("Delek Logistics") announced today that it has commenced an underwritten public offering of $150,000,000 of common units representing limited partner interests in Delek Logistics pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement relating to the offering will also be filed with the SEC. Delek Logistics intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of common units. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Delek Logistics intends to use the net proceeds from the offering (including any net proceeds from the underwriters' exercise of their option to purchase additional common units) to redeem its outstanding convertible preferred units and to repay outstanding borrowings under its revolving credit agreement.
Avigal Soreq, our President and Chief Executive Officer, and certain other of our executives (collectively, the "Executives"), have indicated an interest in purchasing up to $300,000 of the common units offered in the offering at the price offered to the public. Because this indication is not a binding agreement or commitment to purchase, the Executives may elect not to purchase any units in the offering, or the underwriters may elect not to sell any units in the offering to the Executives.

Delek Logistics Partners, LP Announces $150M Proposed Public Offering Of Common Units

Cardiol Therapeutics Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) (TSX:<a href="https://www.benzinga.com/stock/CRDL#TSX">CRDL</a>) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, and for general and administrative expenses, working capital and other expenses.
Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.

Cardiol Therapeutics Files Preliminary Prospectus Supplement For Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed

Above The Noise: Anticipating A New Year And A New Market Environment

Pacer Developed Markets International Cash Cows 100 ETF declares $0.2571 dividend

Q4 2023 - International Equity Review And Outlook

SCHD Vs. COWZ: One Is A Superior Investment Choice

ICOW: Attractive Fundamentals, Average Performance

Pacer Developed Markets International Cash Cows 100 ETF declares quarterly distribution of $0.0571

ICOW: Bringing Cash Flow Focus Overseas

Chart Of The Week: Dollar Index Moving Lower

2024 Global Market Outlook - Q4 Update: Definitely, Maybe

Pacer Developed Markets International Cash Cows 100 ETF declares quarterly distribution of $0.1548

Comments

Pacer Developed Markets International Cash Cows 100 ETF

Noticias

Últimas noticias sobre Pacer Developed Markets International Cash Cows 100 ETF (BATS:ICOW)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL